92 related articles for article (PubMed ID: 27779244)
1. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.
Pontikakis S; Papadaki C; Tzardi M; Trypaki M; Sfakianaki M; Koinis F; Lagoudaki E; Giannikaki L; Kalykaki A; Kontopodis E; Saridaki Z; Malamos N; Georgoulias V; Souglakos J
Pharmacogenomics J; 2017 Dec; 17(6):506-514. PubMed ID: 27779244
[TBL] [Abstract][Full Text] [Related]
2. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
Johnatty SE; Beesley J; Gao B; Chen X; Lu Y; Law MH; Henderson MJ; Russell AJ; Hedditch EL; Emmanuel C; Fereday S; Webb PM; ; Goode EL; Vierkant RA; Fridley BL; Cunningham JM; Fasching PA; Beckmann MW; Ekici AB; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Brown R; Paul J; Lambrechts S; Despierre E; Vergote I; Lester J; Karlan BY; Heitz F; du Bois A; Harter P; Schwaab I; Bean Y; Pejovic T; Levine DA; Goodman MT; Camey ME; Thompson PJ; Lurie G; Shildkraut J; Berchuck A; Terry KL; Cramer DW; Norris MD; Haber M; MacGregor S; deFazio A; Chenevix-Trench G
Gynecol Oncol; 2013 Oct; 131(1):8-14. PubMed ID: 23917080
[TBL] [Abstract][Full Text] [Related]
3. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.
Koti M; Gooding RJ; Nuin P; Haslehurst A; Crane C; Weberpals J; Childs T; Bryson P; Dharsee M; Evans K; Feilotter HE; Park PC; Squire JA
BMC Cancer; 2013 Nov; 13():549. PubMed ID: 24237932
[TBL] [Abstract][Full Text] [Related]
4. Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.
Prahm KP; Høgdall C; Karlsen MA; Christensen IJ; Novotny GW; Knudsen S; Hansen A; Jensen PB; Jensen T; Mirza MR; Ekmann-Gade AW; Nedergaard L; Høgdall E
PLoS One; 2017; 12(3):e0174300. PubMed ID: 28334047
[TBL] [Abstract][Full Text] [Related]
5. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.
Schwarz RF; Ng CK; Cooke SL; Newman S; Temple J; Piskorz AM; Gale D; Sayal K; Murtaza M; Baldwin PJ; Rosenfeld N; Earl HM; Sala E; Jimenez-Linan M; Parkinson CA; Markowetz F; Brenton JD
PLoS Med; 2015 Feb; 12(2):e1001789. PubMed ID: 25710373
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.
Johnatty SE; Tyrer JP; Kar S; Beesley J; Lu Y; Gao B; Fasching PA; Hein A; Ekici AB; Beckmann MW; Lambrechts D; Van Nieuwenhuysen E; Vergote I; Lambrechts S; Rossing MA; Doherty JA; Chang-Claude J; Modugno F; Ness RB; Moysich KB; Levine DA; Kiemeney LA; Massuger LF; Gronwald J; Lubiński J; Jakubowska A; Cybulski C; Brinton L; Lissowska J; Wentzensen N; Song H; Rhenius V; Campbell I; Eccles D; Sieh W; Whittemore AS; McGuire V; Rothstein JH; Sutphen R; Anton-Culver H; Ziogas A; Gayther SA; Gentry-Maharaj A; Menon U; Ramus SJ; Pearce CL; Pike MC; Stram DO; Wu AH; Kupryjanczyk J; Dansonka-Mieszkowska A; Rzepecka IK; Spiewankiewicz B; Goodman MT; Wilkens LR; Carney ME; Thompson PJ; Heitz F; du Bois A; Schwaab I; Harter P; Pisterer J; Hillemanns P; ; Karlan BY; Walsh C; Lester J; Orsulic S; Winham SJ; Earp M; Larson MC; Fogarty ZC; Høgdall E; Jensen A; Kjaer SK; Fridley BL; Cunningham JM; Vierkant RA; Schildkraut JM; Iversen ES; Terry KL; Cramer DW; Bandera EV; Orlow I; Pejovic T; Bean Y; Høgdall C; Lundvall L; McNeish I; Paul J; Carty K; Siddiqui N; Glasspool R; Sellers T; Kennedy C; Chiew YE; Berchuck A; MacGregor S; Pharoah PD; Goode EL; deFazio A; Webb PM; Chenevix-Trench G;
Clin Cancer Res; 2015 Dec; 21(23):5264-76. PubMed ID: 26152742
[TBL] [Abstract][Full Text] [Related]
7. Enterolactone and trabectedin suppress epithelial ovarian cancer synergistically via upregulating THBS1.
Zeng Z; Lin C; Zhang MC; Kossinna P; Wang P; Cao D; Wang J; Xu M; Wang X; Li Q; Xu X; Yang H; Zhu S; Liu GR; Xie K; Yang J; Luo Y; Wang Y; Zhang XH; Lin J; Chen H; Liu SL; Liu H
Phytother Res; 2023 Oct; 37(10):4722-4739. PubMed ID: 37443453
[TBL] [Abstract][Full Text] [Related]
8. High-expressed ACAT2 predicted the poor prognosis of platinum-resistant epithelial ovarian cancer.
Wang J; Yang Z; Bai H; Zhao L; Ji J; Bin Y; Liu Y; Zhang S; Hou H; Li Q
Diagn Pathol; 2024 Jan; 19(1):7. PubMed ID: 38178203
[TBL] [Abstract][Full Text] [Related]
9. HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer.
Teschendorff AE; Lee SH; Jones A; Fiegl H; Kalwa M; Wagner W; Chindera K; Evans I; Dubeau L; Orjalo A; Horlings HM; Niederreiter L; Kaser A; Yang W; Goode EL; Fridley BL; Jenner RG; Berns EM; Wik E; Salvesen HB; Wisman GB; van der Zee AG; Davidson B; Trope CG; Lambrechts S; Vergote I; Calvert H; Jacobs IJ; Widschwendter M
Genome Med; 2015 Oct; 7():108. PubMed ID: 26497652
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells.
Shu C; Zheng X; Wuhafu A; Cicka D; Doyle S; Niu Q; Fan D; Qian K; Ivanov AA; Du Y; Mo X; Fu H
Acta Pharmacol Sin; 2022 Sep; 43(9):2419-2428. PubMed ID: 35031699
[TBL] [Abstract][Full Text] [Related]
11. The Clinical Impact of Death Domain-Associated Protein and Holliday Junction Recognition Protein Expression in Cancer: Unmasking the Driving Forces of Neoplasia.
Pergaris A; Genaris I; Stergiou IE; Klijanienko J; Papadakos SP; Theocharis S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958340
[TBL] [Abstract][Full Text] [Related]
12. High
Li XF; Zhang HB; Huo Y
J Int Med Res; 2022 Nov; 50(11):3000605221135864. PubMed ID: 36366735
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value Estimation of BRIP1 in Breast Cancer by Exploiting Transcriptomics Data Through Bioinformatics Approaches.
Khan U; Khan MS
Bioinform Biol Insights; 2021; 15():11779322211055892. PubMed ID: 34840500
[TBL] [Abstract][Full Text] [Related]
14. Analysis of ceRNA networks and identification of potential drug targets for drug-resistant leukemia cell K562/ADR.
Liu Z; Wang Y; Xu Z; Yuan S; Ou Y; Luo Z; Wen F; Liu J; Zhang J
PeerJ; 2021; 9():e11429. PubMed ID: 34113488
[TBL] [Abstract][Full Text] [Related]
15. Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance.
Gallon J; Loomis E; Curry E; Martin N; Brody L; Garner I; Brown R; Flanagan JM
Clin Epigenetics; 2021 Jun; 13(1):122. PubMed ID: 34090482
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic and tumor suppressor function of MEIS and associated factors.
Gİrgİn B; KaradaĞ-Alpaslan M; KocabaŞ F
Turk J Biol; 2020; 44(6):328-355. PubMed ID: 33402862
[TBL] [Abstract][Full Text] [Related]
17. Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma.
Davidson B; McFadden E; Holth A; Brunetti M; Flørenes VA
Virchows Arch; 2020 Dec; 477(6):857-864. PubMed ID: 32533344
[TBL] [Abstract][Full Text] [Related]
18. Cold Atmospheric Plasma Restores Paclitaxel Sensitivity to Paclitaxel-Resistant Breast Cancer Cells by Reversing Expression of Resistance-Related Genes.
Park S; Kim H; Ji HW; Kim HW; Yun SH; Choi EH; Kim SJ
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31847101
[TBL] [Abstract][Full Text] [Related]
19. Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer.
Xin B; Ji KQ; Liu YS; Zhao XD
J Ovarian Res; 2019 Aug; 12(1):75. PubMed ID: 31399054
[TBL] [Abstract][Full Text] [Related]
20. FN1, SPARC, and SERPINE1 are highly expressed and significantly related to a poor prognosis of gastric adenocarcinoma revealed by microarray and bioinformatics.
Li L; Zhu Z; Zhao Y; Zhang Q; Wu X; Miao B; Cao J; Fei S
Sci Rep; 2019 May; 9(1):7827. PubMed ID: 31127138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
